At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Haematol
Hoofdauteurs: Ganzel, Chezi, Wang, Xin V., Rowe, Jacob M., Richards, Susan M., Buck, Georgina, Marks, David I., Litzow, Mark R., Paietta, Elisabeth M., Foroni, Letizia, Luger, Selina M., Willman, Cheryl L., Mullighan, Charles G., Roberts, Kathryn G., Wiernik, Peter H., Douer, Dan, Lazarus, Hillard M., Tallman, Martin S., Goldstone, Anthony H.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Haematological Malignancy – Clinical
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687130/
https://ncbi.nlm.nih.gov/pubmed/32220069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16616
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items